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ABSTRACT
BACKGROUND: Anhedonia is a core feature of depressive disorders. The 
Galanin N-terminal fragment (1-15) [GAL(1-15)] plays a role in mood regulation 
since it induces depression and anxiogenic-like effects in rats. In this study, we 
analysed GAL(1-15) actions in anhedonic-like behaviours in rats using operant 
and non-operant tests and the areas involved with these effects.
METHODS: GAL(1-15) effects were analysed in saccharin self-administration, 
sucrose preference, novelty-suppressed feeding and female urine sniffing tests. 
The areas involved in GAL(1-15)-mediated effects were studied with positron 
emission tomography (PET) for in vivo imaging, and we analysed the ventral 
tegmental area (VTA) and nucleus accumbens (NAc). GAL(1-15) had effects on 
the mRNA expression of the dopamine transporters Dat and Vmat2; the C-Fos 
gene; the dopamine receptors D1, D2, D3, D5; and the GALRs (GALR1 and 
GALR2).
RESULTS: GAL(1-15) at a concentration of 3 nmol induced a strong 
anhedonia-like phenotype in all tests. The involvement of GALR2 was 
demonstrated with the GALR2 antagonist M871 (3 nmol). The 18F-FDG PET 
images indicated the action of GAL(1-15) over several nuclei of the limbic 
system. GAL(1-15)-mediated effects also involved changes in the expression of 
Dat, Vmat2, D3 receptor and GALR in VTA as well as the expression of C-Fos, 
D1, D2 and D3 and TH immunoreactivity in the NAc. 
CONCLUSIONS: Our results indicated that GAL(1-15) exerts strong anhedonic-
like effects and that this effect was accompanied by changes in the 
dopaminergic mesolimbic system. These results may provide a basis for the 
development of novel therapeutic strategies using GAL(1-15) analogues for the 
treatment of depression and reward-related diseases.
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INTRODUCTION
In 2016, the World Bank Group and the World Health Organization reported that 
mental disorders currently account for 30% of the nonfatal disease burden 
worldwide and that global cost is expected to reach $6 trillion by 2030 (Marquez 
and Saxena, 2016). Major depression is the most frequent mood disorder, with 
a lifetime prevalence that has been reported to range from 7% to 21% (Albert et 
al., 2011). It is associated with substantial functional impairment, diminished 
quality of life, increased burden both for patients and caregivers, and a higher 
risk of mortality.
Although the underlying mechanisms have not yet been clearly defined in the 
last decade, the importance of the roles of neuropeptides, including Galanin 
(GAL), and/or their receptors in the treatment of stress-related mood disorders 
is becoming increasingly apparent (Kormos and Gaszner, 2013; Genders et al., 
2018). 
GAL is a neuropeptide (Tatemoto et al., 1983) that is widely distributed in 
neurons within the central nervous system (CNS) (Jacobowitz et al., 2004). 
Three GAL receptor (GALR1-3) subtypes with high affinities for GAL have been 
cloned (Branchek et al., 2000; Mitsukawa et al., 2008). GALR1 and GALR3 
mainly activate the inhibitory G proteins Gi/Go while GALR2 mainly couples to 
Gq/G11 to mediate excitatory signalling (Branchek et al., 2000). GAL and its 
receptors evoke depression-related and anxiety-like behaviours (Juhasz et al., 
2014). GAL-overexpressing mice and rodents in which GAL was infused either 
intraventricularly (i.c.v) or into the ventral tegmental area showed an increase in 
immobility during a forced swimming test (FST) that was indicative of 
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depression-like behaviour (Kuteeva et al., 2005; Kuteeva et al., 2007; Weiss et 
al., 1998). Additionally, in a genetic rat model of depression, the Flinders 
Sensitive Line, upregulation of the GAL receptor binding sites was found in the 
dorsal raphe nucleus, which has been linked to high immobility in the FST 
(Bellido et al., 2002). However, intraperitoneal (i.p.) injections of GALR2 
agonists exhibited antidepressant-like effects and two non-selective GALR 
agonists, galnon and galmic, decreased immobility times in the FST (Bartfai et 
al., 2004; Lu et al., 2005). These discrepancies are attributed to the different 
physiological roles of the GAL receptor subtypes (Swanson et al., 2005; 
Kuteeva et al., 2008b; Barr et al., 2006). Thus, the activation of GALR1 and 
GALR3 results in a depression-like behaviour while stimulation of GALR2 leads 
to antidepressant-like effects (Bartfai et al., 2004; Lu et al., 2005; Kuteeva et al., 
2008a). Recently, it has also been described that, in humans, the GAL gene 
and its receptor GALR3 are differentially methylated and expressed in brains of 
major depression subjects in a region- and sex-specific manner (Barde et al., 
2016).
Not only GAL but also N-terminal fragments similar to GAL(1-15) are active in 
the CNS (Hedlund and Fuxe, 1996; Diaz-Cabiale et al., 2005; Diaz-Cabiale et 
al., 2007; Diaz-Cabiale et al., 2010). Recently, we demonstrated that GAL(1-15) 
induces strong depression-related behaviour in rats and these effects were 
significantly stronger than the ones induced by GAL (Millon et al., 2015). We 
analysed GAL(1-15)-mediated effects in two tests developed to screen 
monoamine-based antidepressant drugs: the FST and the tail suspension test 
(TST). Both assess the response to an inescapable stressor, provoking despair-
based behaviour/immobility and, in these tests, GAL(1-15) induced depression-
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like behaviour since significant increases in immobility were observed (Millon et 
al., 2015). We demonstrated that GALR1-GALR2 heteroreceptor complexes in 
the dorsal hippocampus and DR, areas rich in GAL(1-15) binding sites (Hedlund 
et al., 1992) were involved in these effects (Millon et al., 2015) (Borroto-Escuela 
et al., 2014). 
Moreover, GAL(1-15) also induced an anxiogenic-like effect in the open field 
and the light/dark test (Millon et al., 2015). Since, in animal models, anxiety can 
by considered an element of the depression, the fact that GAL(1-15) induced a 
strong depression and anxiogenic-like effects in all the tests indicated a 
potential role for GAL(1-15) in mood disorders, especially in depression.
However, the role of GAL(1-15) in an endophenotype that represents a key 
symptom of depression, such as reward-related and anhedonic behaviour, is 
still unknown. Anhedonia is considered to be a core feature of major depressive 
disorders as, for example, the Diagnostic and Statistical Manual of Mental 
Disorders, fifth edition (DSM-V) requires that either a depressed mood or 
anhedonia be present to propose this diagnosis. Furthermore, the lack of 
reactivity and anhedonia are key diagnostic criteria for the DSM-V melancholic 
subtype of major depression, and the presence of anhedonia has been shown 
to be predictive of an antidepressant response (Gorwood, 2008).
The purpose of the present study was to assess the role of 
intracerebroventricular (i.c.v.) GAL(1-15) in anhedonic behaviour using a widely 
accepted approach to assess reward seeking behaviour in operant and 
nonoperant tests: saccharin self-administration, sucrose preference, novelty-
suppressed feeding and female urine sniffing tests. Moreover, the involvement 
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of GALR2 in the effects induced by GAL(1-15) were analysed with the selective 
GALR2 antagonist M871. To investigate the areas involved in GAL(1-15)-
mediated effects, positron emission tomography (PET) for in vivo imaging of 
metabolic processes was performed. We also analysed transcriptional changes 
in the ventral tegmental area (VTA) and nucleus accumbens (NAc), which are 
essential nuclei in reward processes, and the effect of GAL(1-15) on the mRNA 
expression of dopamine transporters Dat and Vmat2; the C-Fos gene; the 
dopamine receptors D1, D2, D3, D5; and the GALRs (GALR1 and GALR2).
MATERIALS AND METHODS
Animals
Male Sprague Dawley rats (225–250 g) were obtained from Criffa and 
maintained in a humidity- and temperature-controlled room. All animal 
experimentation was conducted in accordance with the University of Málaga 
Guidelines for the Care and Use of Laboratory Animals.
Detailed descriptions are available in the supplemental information on the 
animal controlled-conditions, surgical preparation and i.c.v. injections.
Saccharin Self-administration
Training was achieved using a modification of the protocol reported by (Alen et 
al., 2009). Briefly, rats were placed on a water restriction schedule for 2-4 days 
to facilitate training of lever pressing. The rats were trained to self-administer 
saccharin 0.2% (w/v) in 30-min daily sessions for two weeks on a fixed ratio 1 
schedule of reinforcement in which each response resulted in the delivery of 0.1 
ml of fluid. At this point, saccharin self-administration training continued until the 
































































Millón et al., 2018 Journal of Psychopharmacology
7
animals reached stable baseline responding. During the test sessions, the 
responses on the active lever and number of saccharin reinforcements were 
recorded (see the supplemental information for details).
Three sets of experiments were conducted in the saccharin self-administration 
test. In the first set of experiments, a dose-response curve of GAL(1-15) was 
generated. For this, groups of rats received i.c.v. 1 nmol or 3 nmol GAL(1-15) or 
vehicle 15 min before the test. In the second set of experiments, the effects in 
saccharin self-administration of GAL and GAL(1-15) were compared. Groups of 
rats received i.c.v. 3 nmol GAL, 3 nmol GAL(1-15) or vehicle 15 min before the 
test. In the last set of experiments, groups of rats received i.c.v. 3 nmol GAL(1-
15) was combined with GALR2 antagonist 3 nmol M871 15 min before the 
measures to study the role of GALR2. The doses employed and the injection 
protocol were based on those of previous studies (Millon et al., 2015).
The general schema of the experimental design is shown in Figure 1A.
Sucrose Preference Test
Anhedonia was assessed using the sucrose preference test (SPT), performed 
as described previously (Marco et al., 2017) with minor modifications (see the 
supplemental information for details). Briefly, on the testing day, rats were 
allowed free access to two-bottles: one containing 1% (w/v) sucrose solution 
and the other containing tap water. After 2, 8 and 24 h, the bottles were 
weighed to calculate the sucrose intake (g/kg) and sucrose preference (sucrose 
preference=sucrose consumption /(water + sucrose consumption) x100), which 
reflected the rats’ anhedonia levels.
































































Millón et al., 2018 Journal of Psychopharmacology
8
In the experiment, groups of rats received i.c.v. 3 nmol GAL(1-15) or vehicle, 
based on a previous study (Millón et al., 2015), and the sucrose intake and 
sucrose preference were measured at 2, 8 and 24 h after injection.
The general schema of the experimental design is shown in Figure 1B.
Novelty Suppressed feeding
The NSF test was carried out during the 10 min period as previously described 
(Pascual-Brazo et al., 2012) with some modifications (see the supplemental 
information for details). Briefly, all rats were deprived of food for 24 h before the 
test. The testing apparatus consisted of a plastic box (60x40x20 cm) with a 
single pellet of food in the centre of the box on white circular filter paper. In the 
experiment, groups of rats received i.c.v. 3 nmol GAL(1-15) or vehicle 15 min 
before the test, based on a previous study (Millón et al., 2015), and the latency 
of the first feeding episode was recorded.
Female Urine Sniffing Test
The female urine sniffing test (FUST) was conducted as described previously 
(Malkesman et al., 2012) (see the supplemental information for details). Briefly, 
the test had three phases: a single exposure to the cotton tip dipped in sterile 
water; an interval during which no applicator was presented to the animal; and a 
single exposure to a cotton tip infused with fresh urine or water, during which 
the time spent sniffing was measured.
The animals receiving 3 nmol GAL(1-15) or vehicle were injected 15 min before 
exposure to the urine or water.
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The general schema of the experimental design of NSF and FUST is shown in 
Figure 1B.
PET studies
The 18F-FDG PET imaging was performed at Unidad de Imagen Molecular, 
CIMES, Spain in a dedicated small animal Philips MOSAIC tomograph 
(Cleveland, OH, USA) system as previously described (Prieto et al., 2011). 
Animals were administered icv with CSFa and, after 3-4 days, with Gal(1-15) (3 
nmol). The doses employed and the injection protocol were based on previous 
works (Millon et al., 2015). Immediately after the treatment, the 18F-FDG (43.6 ± 
5.5 MBq in 0.3 ml of 0.9% NaCl) was injected through the tail vein. After an 
awake uptake period of 25 minutes to ensure the incorporation of 18F-FDG 
during drug-induced behavioural effects (Prieto et al., 2011), the animals were 
anaesthetized and placed prone on the PET scanner bed to perform static 
acquisition for 30 min at three different timepoints (30, 60 and 90 min) after 
tracer administration (see the supplemental information for details).
Statistical analysis of PET images
Differences in 18F-FDG uptake between aCSF- and GAL[1-15]-injected animals 
were assessed using software package SPM8 under the general lineal model 
framework and whole brain contrast analysis. A t-test was performed for each 
timepoint (30, 60 and 90 min), and the differences between the groups were 
represented by a map of t-statistics. The contrast images were yielded based 
on a voxel-level height threshold of p<0.01 (uncorrected) and a cluster-extend 
threshold of 100 voxels. Resultant clusters are shown on a SAMIT rat RM 
template in Paxinos and Watson space.
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Genes expression in VTA and NAc
Rats from NSF and FUST experiments (Figure 1B) were euthanized by 
decapitation 1 h after a single i.c.v. administration of GAL(1-15) 3 nmol or 
vehicle and the brains were rapidly removed and frozen until use. The dose and 
time selected were based by previous works (Millón et al., 2015; García-Perez 
et al., 2016). The nuclei dissections were conducted as described (Garcia-
Perez et al., 2016) with modifications (see supplemental information for details).
RNA isolation and quantitative real-time polymerase chain reaction analysis
The procedure to perfo m RNA isolation and real-time polymerase chain 
reactions (RT-PCRs) was described previously (Millon et al., 2015; Millon et al., 
2017a; Flores-Burgess et al., 2017) (see the supplemental information for 
details). 
The primer sequences used to evaluate the mRNA expression levels of the 
genes Gapdh, C-Fos, Dat, Vmat2, D1, D2, D3, D5, GALR1 and GALR2 are 
shown in Table S1.
Tyrosine Hydroxylase immunohistochemistry
Rats from the NSF and FUST experiment (Figure 1B) were perfused 
transcardially 90 min after a single i.c.v. administration of 3 nmol GAL(1-15) or 
vehicle. The TH immunohistochemistry was conducted in NAc and CPu with 
modifications as previously described (Cadoni et al., 2017) (see the 
supplemental information for details).
Double immunofluorescence
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The procedures have been used previously (Millon et al., 2015). Primary 
antibodies directed to GALR2 (rabbit polyclonal, Alomone Lab, 1/250) and 
GALR1 (goat polyclonal, Santa Cruz Biotechnology INC, EEUU, 1:250) were 
used (see supplemental information for details). Double immunolabelling was 
performed in sections of the striatum and VTA of rats without treatment (Figure 
S1).
Statistical Analysis
Data are presented as the mean ± standard error of the mean, and sample 
numbers (n) are indicated in figure legends. All data were analysed using 
GraphPad PRISM 6.0 (GraphPad Software). For comparing two experimental 
conditions, Student’s unpaired t-tests were performed. Otherwise, one-way or 
two-way analysis of variance (ANOVA) followed by Fisher’s least significant 
difference (LSD) comparison post-test was performed. Differences were 
considered significant at P < 0.05 (*P < 0.05, ** P < 0.01, *** P < 0.001).
RESULTS
Behavioural Studies
GAL(1-15) induced an anhedonic-like effect.
Effects of GAL(1-15) in the saccharin self-administration test
GAL(1-15) at a concentration of 3 nmol significantly decreased the number of 
reinforcements of saccharin self-administration (one-way ANOVA, F2,26=5.743, 
p<0.01, Fisher’s LSD post hoc test: p<0.01) by 43% (Figure 2A) fifteen minutes 
after administration. GAL(1-15) at a concentration of 1 nmol lacked the effect on 
the number of saccharin reinforcements.
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In the comparison between GAL and GAL(1-15) in the saccharin self-
administration test, one-way ANOVA revealed a significant difference between 
the N-terminal fragment GAL(1-15) and GAL. GAL(1-15) significantly reduced 
the number of saccharin reinforcements compared with GAL (one-way ANOVA, 
F2,28=6.068, p<0.01, Fisher’s LSD post hoc test: p<0.01) (Figure 2B). GAL 
lacked an effect on the number of saccharin reinforcements compared with the 
control group (Figure 2B).
GALR2 antagonist M871 blocked GAL(1-15)-mediated effects in the saccharin 
self-administration test. The GALR2 antagonist M871 significantly blocked the 
decrease in the number of saccharin reinforcements (one-way ANOVA, 
F3,28=3.449, p<0.05, Fisher’s LSD post hoc test: p<0.05) induced by GAL(1-15) 
administration (Figure 2C). M871 alone at the dose of 3 nmol lacked an effect 
on the number of saccharin reinforcements.
Effects of GAL(1-15) in the sucrose preference test (SPT)
GAL(1-15) at a concentration of 3 nmol decreased the sucrose intake (two-way 
ANOVA (group x time), F2,26=4.8836, p<0.05) at 8 hours (Fisher’s LSD post hoc 
test p<0.05) and 24 hours (Fisher’s LSD post hoc test p<0.01) after 
administration (Figure 3A). Moreover, i.c.v. injection of 3 nmol GAL(1-15) 
induced a not significant decrease in sucrose preference (two-way ANOVA 
(Group), F1,13=4.039, p=0.0656) at 2 h, 8 h and 24 h (Figure 3B).
Regarding water intake (Table S2), no differences (two-way ANOVA (Time x 
Group), F2,26=0.2915, p=0.7494) were found at any timepoint after GAL(1-15) 
i.c.v. administration.
Effects of GAL(1-15) in the novelty suppressed feeding (NSF) test
































































Millón et al., 2018 Journal of Psychopharmacology
13
In the NSF, GAL(1-15) at the dose of 3 nmol significantly increase the latency to 
eat (t15=5.147, p<0.001; Figure 4A) by 80%. 
Effects of GAL(1-15) in the female urine sniffing test (FUST)
In this test, the overall one-way ANOVA revealed a significant difference 
between the sniffing duration of water cotton and female urine cotton (one-way 
ANOVA, F2,23=14.39, p<0.001, Fisher’s LSD post hoc test: p<0.001 urine-CSFa; 
p<0.01 urine-GAL(1-15); Figure 4B). Moreover, 3 nmol GAL(1-15) induced a 
significant decrease in sniffing duration over urine cotton to compare with the 
urine-CSFa group (one-way ANOVA, F2,23=14.39, p<0.001, Fisher’s LSD post 
hoc test p<0.05; Figure 4B).
No differences were found between the water-CSFa and water-GAL(1-15) 
groups in sniffing duration (t10=1.480, p=0.084; Figure 3C.)
PET Studies
The GAL(1-15) treatment induced a significant decrease in [18F]FDG uptake in 
the hippocampus (bilateral) and thalamus at 30 min. This reduction was 
maintained in both nuclei at 60 min and 90 min (Figure 5). In addition, a 
reduced uptake was also observed in the striatum (caudate putamen and 
external globus pallidum) at 30 min. Moreover, the administration of the GAL 
fragment induced an increase in [18F]FDG uptake after 30 min and 60 min in the 
prefrontal cortex and in the piriform cortex after 60 min (Figure 5).
Neurochemical Studies
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GAL(1-15) affects the mRNA expression of the dopamine transporters Dat 
and Vmat2 and of C-Fos in the ventral tegmental area (VTA) and the 
accumbens nucleus (NAc).
As shown in Figure 6, GAL(1-15) at a dose of 3 nmol produced a significant 
decrease in the mRNA levels of Dat (t6=1.988, p<0.05; Figure 6A) and Vmat2 
(t6=2.480, p<0.05; Figure 6B) in VTA 1 hour after its administration. However, 
GAL(1-15) did not affect C-Fos mRNA expression in the nucleus (Figure 6C). In 
the NAc, 3 nmol i.c.v. GAL(1-15) induced a significant decrease in the 
expression of C-Fos mRNA (t7=2.329, p<0.05; Figure 6D) 1 hour after 
administration.
Additionally, C-Fos mRNA expression was measured in other regions, such as 
the dentate gyrus in the hippocampus, where GAL(1-15) produced a significant 
increase compared with the control group (mRNA expression: Control: 
1.39±0.2; GAL(1-15): 2.60±0.2; t6=3.352, p<0.01).
GAL(1-15) affects the mRNA expression of dopamine receptors in the 
ventral tegmental area (VTA) and the accumbens nucleus (NAc)
In the VTA, the administration of GAL(1-15) induced a significant increase in the 
mRNA expression of D3 1 hour after injection (t7=1.981, p<0.05; Figure 7C). No 
differences were found in D1, D2 and D5 receptor expression after GAL(1-15) 
administration in the VTA (Figure 7A,B, and D). 
As shown in the second part of Figure 7, GAL(1-15) 3 nmol significantly 
increased the mRNA expression of D1 (t7=2.019, p<0.05; Figure 7E), D2 
(t7=2.008, p<0.05; Figure 7F) and D3 (t6=3.045, p<0.05 Figure 7G) in the NAc, 
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1 hour after its administration. GAL(1-15) lacked an effect on mRNA expression 
of D5 compared with the control group in the NAc.
GAL(1-15) effects in mRNA expression of Galanin receptors in the Ventral 
Tegmental Area (VTA) and Accumbens nucleus (NAc).
Using double immunolabelling, we observed a colocation of GALR1 and GALR2 
immunoreactivity in the nerve cells of the VTA (Figure S1A), in both the core 
(NAcC; Figure S1B) and shell (NAcSh; Figure S1C) of the NAc and in the dorsal 
striatum (caudate putamen; CPu) (Figure S1D).
The administration of GAL(1-15) modified GALR2 and GALR1 expression in the 
VTA, producing a significant increase in GALR2 mRNA levels (t7=1.970, 
p<0.05; Table 1) and a slight increase in GALR1 expression (t7=0.980, p=0.17; 
Table 1), suggesting the involvement of GALR in GAL(1-15)-mediated effects. 
GAL(1-15) decreased TH immunoreactivity in the striatum.
As shown in Table 2, i.c.v. administration of GAL(1-15) reduced TH 
immunoreactivity in the striatum. GAL(1-15) induced a significant decrease in 
TH immunoreactivity in the NAc core (t4=2.694, p<0.05; Table 2) 90 min after its 
administration. Moreover, the injection of GAL(1-15) induced a slight decrease 
in TH immunoreactivity in the NAc Shell. In the dorsal striatum (CPu); the same 
response pattern was observed in that GAL(1-15) produced a slight reduction in 
TH immunoreactivity 90 min after its injection (Table 2).
DISCUSSION
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In the present study, we demonstrated for the first time that GAL(1-15) induced 
a strong anhedonia-like phenotype in non-operant and operant models: the 
sucrose preference test (SPT), the novelty suppressed feeding (NSF) test, the 
female urine sniffing test (FUST) and the operant saccharin self-administration 
test. GALR2 was involved in this effect since the specific GALR2 antagonist 
M871 blocked GAL(1-15) mediated action in saccharin self-administration. 
18F-FDG PET images demonstrated that GAL(1-15) induced modifications in 
FDG uptake in vivo in limbic nuclei, such as the hippocampus, the thalamus, 
striatum, the prefrontal cortex and the piriform cortex. Importantly, the 
mechanism of the GAL(1-15) behaviour-mediated effect  was accompanied by 
changes in the VTA and NAc, which are the key nuclei of the dopaminergic 
mesolimbic circuit and are critical for the neurobiological bases of anhedonia 
(Der-Avakian and Markou, 2012). Changes in the expression of the dopamine 
transporters DAT and Vmat2 and in the D3 and Galanin receptors in the VTA 
were observed. Changes in the immediate-early gene C-Fos and in the D1, D2 
and D3 receptors in NAc were also observed. The relevance of the mesolimbic 
circuit as a target for GAL(1-15) was also supported by the effect of GAL(1-15) 
on the TH immunoreactivity in the striatum.
In the operant self-administration models used as a tool for the study of reward-
seeking motivated behaviour (Sanchis-Segura and Spanagel, 2006; Ettenberg, 
2009), GAL(1-15) induced a strong reduction in the number of reinforcements in 
saccharin self-administration, suggesting that GAL(1-15) induced a loss of 
motivational behaviour induced by an artificial reinforcer.
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In this work, we also studied the differential role of GAL(1-15) and GAL in 
reward-seeking motivated behaviour using the saccharin self-administration 
paradigm. GAL(1-15), but not GAL, induced a strong reduction in the number of 
reinforcements, suggesting that only GAL(1-15) reduces the motivation to 
consume the reward. We have previously described a different action of GAL 
and GAL(1-15) in behaviour functions (Millon et al., 2015; Millon et al., 2016; 
Millon et al., 2017b; Millon et al., 2017a). GAL(1-15) induces depression-related 
and anxiogenic-like effects in rats, and these effects were significantly stronger 
than the one induced by GAL (Millon et al., 2015). Furthermore, GAL(1-15) 
produced a strong reduction in the alcohol intake and preference in a model of 
voluntary alcohol intake, showing a different role than that of the complete GAL 
molecule (Millon et al., 2017a). The differential action between GAL and 
GAL(1–15) was observed not only in behavioural functions but also in central 
cardiovascular regulation (Diaz-Cabiale et al., 2005; Diaz-Cabiale et al., 2010). 
Therefore, the fact that the effects of GAL(1-15) in the saccharin self-
administration were different than the effects induced by GAL validated and 
extended the view of a specific role of GAL(1-15) in reward-related and 
anhedonic behaviour.
We demonstrated that GALR2 is involved in the anhedonia-like effects induced 
by GAL(1-15) since the administration of the specific GALR2 antagonist M871 
blocked the effects of GAL(1-15). The formation of heterodimers between 
GALR1/GALR2 has been proposed to be the main mechanism of action of 
GAL(1-15) (Fuxe et al., 2008; Fuxe et al., 2012; Millon et al., 2015; Borroto-
Escuela et al., 2014). Therefore, the anhedonia-like effects induced by GAL(1-
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15) are mediated by GALR2, confirming that GAL(1-15) acts through the 
heterodimer GALR1/GALR2.
Not only in the operant model but also in non-operant models using several 
reinforcements, such as the natural reinforcer sucrose (SPT) (Willner, 2005; 
Walser, 2011; Der-Avakian and Markou, 2012), the food (NSF) (Walser, 2011; 
Ferres-Coy et al., 2016) and the sexual motivation behaviour (FUST) 
(Malkesman et al., 2010; Malkesman et al., 2012), GAL(1-15) induced a 
significant anhedonic-effect, confirming an important role for this neuropeptide 
in anhedonia, which is a core feature of Major Depressive Disorders.
We have used 18F-FDG Positron Emission Tomography for in vivo imaging of 
metabolic processes (Eidelberg, 2009) as a powerful tool to study the effect of 
GAL(1-15). GAL(1-15) treatment altered glucose metabolism in several nuclei of 
the limbic system, decreasing FDG uptake in the hippocampus and thalamus or 
in several areas of the striatum and increasing the uptake in the prefrontal and 
piriform cortexes. These results are in agreement with previous works in which 
the hippocampus, the striatum or the prefrontal cortex were targeted for GAL(1-
15) (Millon et al., 2015; Millon et al., 2016; Millon et al., 2017a) (Flores-Burgess, 
2018), which are areas rich in GAL-fragment binding sites (Hedlund et al., 1992). 
However, we cannot disregard GAL(1-15) action in other small nuclei such as 
the dorsal raphe (Millon et al., 2015), VTA or NAc because of the limited 
resolution of PET scans (Prieto et al., 2011).
We further investigated GAL(1-15) effects on the key mesolimbic reward nodes, 
the VTA and the NAc, by evaluating the effects of GAL(1-15) treatment on the 
expression of genes that regulate dopaminergic activity, which is critical for the 
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reward system and anhedonia (Russo and Nestler, 2013; Nestler and Carlezon, 
2006; Bressan and Crippa, 2005). GAL(1-15) induced a strong reduction in the 
expression of the dopamine transporters DAT and Vmat2 in the VTA. Since 
DAT regulates extracellular DA levels in the extracellular space into presynaptic 
DA terminals after DA release and since Vmat2 packages monoamines into 
synaptic vesicles for subsequent release (Garcia-Perez et al., 2016), our results 
suggest that GAL(1-15) affects the production and release of DA. In addition, 
GAL(1-15) also increased D3 receptor expression in the VTA, which is a 
receptor localized not only in the postsynaptic region but also in the presynaptic 
region, where it modulates both dopamine synthesis and release, thereby 
acting as an autoreceptor (Leggio et al., 2013; Diaz et al., 2000).
Moreover, the colocalization, as determined by procedures previously used 
(Millon et al., 2015), of GALR1 and GALR2 in the VTA (Figure S1A) and the 
increased GALR1 and GALR2 expression induced by GAL(1-15) in this area 
confirmed that the VTA is a target of GAL(1-15). Since GAL(1-15) acts through 
a GALR1/GALR2 heteroreceptor complex that inhibits the Gq/G11-mediated 
signalling of the GALR2 protomer and switches it towards Gi/o-mediated 
signalling, thereby enhancing Gi/o-mediated signalling of GALR1 in the 
GALR1–GALR2 heterodimer (Millon et al., 2015; Borroto-Escuela et al., 2014). 
This enhancement of the Gio-mediated signal reduces DA formation in this cell, 
which could explain the functional results found in this work.
In the NAc, GAL(1-15) reduced C-Fos mRNA expression and TH 
immunoreactivity and increased the numbers of the D1, D2 and D3 receptors. 
The reduction of DA release suggested by our experiments would explain the 
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reduction in neural activity (Manning et al., 2017) in the NAc and can explain 
the increase in DA receptor expression as a compensatory effect.
Altogether, these modifications induced by GAL 1-15 suggested that its main 
effect on the mesolimbic pathway is the structural and functional reorganization 
of the dopaminergic system, which likely leads to its functional inhibition.
The results of the present work are in agreement with previous work that 
showed that the effect of GAL(1-15) in EtOH consumption was directly related 
to the dopaminergic system and the striatum (Millon et al., 2017a).
In conclusion, our results indicate that GAL(1-15) induces a strong anhedonia-
like phenotype in rats, likely due to the involvement of the dopaminergic 
mesolimbic system, which is critical for the reward system and anhedonia 
(Russo and Nestler, 2013; Nestler and Carlezon, 2006; Gold et al., 2018; 
Bressan and Crippa, 2005). Motivation is a brain function that is based on this 
dopaminergic system, which is critically compromised in several 
neuropsychiatric diseases/conditions, including depression. Our results may 
help to better understand the complex problem of impaired motivation (i.e., 
anhedonia) and may provide a basis for the development of novel therapeutic 
strategies using GAL(1-15) analogues for the treatment of depression and 
reward-related diseases.
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Figure 1. Experimental design of the procedures for saccharin self-
administration (A), the sucrose preference test (SPT) (B), and the novelty 
suppressed feeding test (NSF) and female urine sniffing test (C). i.c.v, 
intracerebroventricular. 
Figure 2. Role of Galanin (1-15) [GAL(1-15)] on operant self-administration of 
saccharin 0,2% in rats. A) Dose-response curve of the effect GAL(1-15) on self-
administration of saccharin. GAL(1-15) (n=7-10 animals) was administered 
intracerebroventricularly (i.c.v.) 15 min before the test session. Cerebrospinal 
fluid-injected rats were used as the control group (n= 12 animals). B) The effect 
of administration of Galanin (GAL) and GAL(1-15) on the self-administration of 
saccharin. GAL (3 nmol/rat) and GAL(1-15) (3 nmol/rat; n=8-9 animals) were 
injected i.c.v. 15 min before the test. Cerebrospinal fluid-injected rats were used 
as the Control group (n=14 animals). C) The effects of the co-administration of 
GALR2 receptor antagonist M871 (3 nmol/rat) and GAL(1-15) (n=7-9 animals) 
on the self-administration of saccharin. Treatments were injected i.c.v. 15 min 
before the test. Cerebrospinal fluid-injected rats were used as Control groups 
(n=9 animals). Vertical bars represent a mean ± standard error of the mean of 
the Number of saccharin Reinforcements during the test period. *p<0.05 and 
**p<0.01 versus the rest of the groups according to a one-way ANOVA followed 
by Fisher's least significance difference test.
Figure 3. Effect of administration of Galanin (1-15) [GAL(1-15)] in the sucrose 
preference test with 1% sucrose concentration in rats. GAL(1-15) (3 nmol/rats; 
n= 8-9 animals per group) were administered intracerebroventricularly 2, 8 and 
24 h before the measures. Cerebrospinal fluid-injected rats were used as the 
Control group (n= 7 animals). Vertical bars represent the mean ± standard error 
of the mean of sucrose intake (g/kg) (A,) and preference (percent) (B) during 
the different period. *p<0.05 and **p<0.01 versus the Control group according 
to a repeated measures two-way ANOVA followed by Fisher's least significance 
difference test.
Figure 4. Effect of the administration of Galanin (1-15) [GAL(1-15)] in the 
novelty-suppressed feeding test (NSF) (A) and the female urine sniffing test 
(FUST) (B,C) in rats. (A) GAL(1-15) (3 nmol/rat; n= 9 animals per group) were 
administered intracerebroventricularly 15 min before the test. Cerebrospinal 
fluid-injected rats were used as the Control group (n= 8 animals). Vertical bars 
represent the mean ± standard error of the mean of the latency period of the 
first feeding (s) during the test. ***p<0.001 versus Control group according to a 
Student’s t-test. (B) GAL(1-15) (3 nmol/rat; n= 7 animals) were administered 
i.c.v. 15 min before the test. Cerebrospinal fluid-injected rats (CSFa) were used 
as the Urine-CSFa group (n= 6 animals). Vertical bars represent the mean ± 
standard error of the mean of the sniffing duration of water (n= 14 animals) or 
oestrus female urine (s) during the test. ***p<0.001; **p<0.01 and *p<0.05 
according to a one-way ANOVA followed by Fisher’s least significant difference 
test. (C) GAL(1-15) (3 nmol/rat; n= 6 animals) were administrated icv 15 min 
before the test. Cerebrospinal fluid-injected rats (CSFa) were used as the 
Water-CSFa group (n= 6 animals). Data represent the mean ± standard error of 
the mean of sniffing duration of water during the test. No differences were found 
according Student’s t-test.
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Figure 5. Effects of GAL(1-15) on rat brain glucose metabolism. Statistical 
parametric mapping (SPM) analysis results displayed on coronal, horizontal and 
sagittal brain sections showing regions with significantly reduced 
(hypometabolism, blue) and increased (hypermetabolism, red) uptake of 
[18F]FDG at 30, 60 and 90 min after i.c.v. GAL(1-15) administration (p<0.01 
uncorrected, clusters with extended threshold k = 100). 
Figure 6. Effects of Galanin (1-15) [GAL(1-15)] in the ventral tegmental area 
(VTA) mRNA expression of (A) Dat, (B) Vmat2, (C) C-Fos or nucleus 
accumbens (NAc) mRNA expression of (D) C-Fos in rats. GAL(1-15) (3 
nmol/rat) was injected intracerebroventricularly 1 hour before the measures. 
Cerebrospinal fluid-injected rats were used as the Control group. Vertical bars 
represent the mean ± standard error of the mean (n=4-5 animals per group). 
*p<0.05 versus Control group according to a Student’s t-test.
Figure 7. Effects of Galanin (1-15) [GAL(1-15)] in the expression of the 
dopamine receptors D1, D2, D3 and D5 in the ventral tegmental area (VTA) (A-
D) or nucleus accumbens (NAc) (E-H) in rats. GAL(1-15) (3 nmol/rat) was 
injected intracerebroventricularly 1 hour before the measures. Cerebrospinal 
fluid-injected rats were used as the Control group. Vertical bars represent the 
mean ± standard error of the mean (n=4-5 animals per group). *p<0.05 versus 
Control group according to a Student’s t-test.
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Table 1. Galr1 and Galr2 mRNA expression.
Galr1 Galr2
Control GAL(1-15) Control GAL(1-15)
VTA 0.70±0.2 1.21±0.4 1.22±0.1 1.66±0.1*
NAc 0.72±0.2 0.47±0.1 0.99±0.1 0.98±0.1
Table 1. Effects of Galanin (1-15) [GAL(1-15)] in the expression of Galanin 
receptors Galr1 and Galr2 in the Ventral Tegmental Area (VTA) or Nucleus 
Accubens (NAc) in rats. GAL(1-15) (3nmol/rat) was injected 
intracerebroventricular 1 hour before the measures. Cerebrospinal fluid-injected 
rats were used as Control group. n=4-5 animals per group. *p<0.05 versus 
Control group according to Student’s t-test.
Table 2. Tyrosine Hydroxylase immunoreactivity in the Striatum.
Control GAL(1-15)
NAc Shell 24.2±4.7 16.5±4.0
NAc Core 6.7±0.3 4.5±0.7*
Dorsal Striatum (CPu) 6.1±0.9 4.9±0.8
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SUPPLEMENTARY MATERIAL AND METHODS
Animals
Male Sprague Dawley rats (body weight 225–250g, age 8 weeks) were 
obtained from Criffa and maintained in a humidity- and temperature-controlled 
(20–22oC) room. The rats in the saccharin self-administration and sucrose 
preference test were during the entire protocol maintained on a 12-hour 
reversed light/dark cycle (lights off at 10 am) whereas the other rats kept on 12- 
/hour light/dark cycle. The animals had free access to food pellets and tap water. 
Experimental procedures were approved by the Institutional Animal Ethics 
Committee of the University of Málaga, in accordance with the European 
Directive (86/609/EEC) and Spanish Directive (Real Decretory 53/2013).
Intracerebroventricular Injections
This protocol has been used previously (Millon et al., 2015; Diaz-Cabiale et al., 
2011). Briefly, the rats were anesthetized intraperitoneally with equitesin 
(3.3mL/kg body weight), and stereotaxically implanted with a unilateral chronic 
22-gauge stainless-steel guide cannula into the right lateral cerebral ventricle 
using the following coordinates: 1.4mm lateral and 1mm posterior to bregma, 
and 3.6mm below the surface of the skull (Paxinos, 1986). After surgery, 
animals were individually housed and allowed a recovery period of 7 days. The 
injections in the lateral ventricle were performed using a 26-gauge stain less-
steel injection cannula connected via a PE-10 tubing to a Hamilton syringe. The 
total volume was 5 μl per injection and the infusion time was 1min.
Solutions were prepared freshly and the peptides were dissolved in artificial 
cerebrospinal fluid (composition is 120nM NaCl, 20nM NaH2CO3, 2nM KCl, 
0.5nM KH2PO4, 1.2nM CaCl2, 1.8 nM MgCl2, 0.5 nM Na2SO4, and 5.8 nM D-
glucose, pH 7.4). GAL was obtained from NeoMPS, Strasbourg, France; 
GAL(1–15) and the GALR2 receptor antagonist M871 were obtained from 
Tocris Bioscience,Bristol,UK.
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Saccharin Self-administration
Training and testing were conducted in standard operant chambers. Each 
chamber was equipped with a drinking reservoir (0.10 ml) positioned 4 cm 
above the grid floor in the center of the front panel of the chamber, and two 
retractable levers were located 3 cm to right and left of the dinking receptacle 
(one being the active lever, and the other being the inactive lever). Visual 
stimuli were presented via a light located on the front panel. 
Sucrose Preference Test
Briefly, rats were habituated to 1% sucrose solution for two days with free 
access to water and sucrose in their home cage. To prevent possible effects of 
side preference in drinking behaviour, the position of the bottles was switched 
every 24h. After this adaptation, rats were deprived of water for 18 h. Food was 
available during the testing session. 
Novelty Suppressed feeding
Novelty Suppressed feeding (NSF) is a conflict test that elicits competing 
motivations: the drive to eat and the fear of venturing into the center of the 
arena (Ferres-Coy et al., 2016). The testing apparatus consisted of a plastic box 
(60x40x20 cm), with its floor covered with wooden bedding (2 cm) and with a 
single pellet of food in the center of the box on white circular filter paper (10 cm 
in diameter). Each rat was placed in the corner of the testing arena and the 
latency of the first feeding episode was recorded. Non-feeding behaviours (e.g. 
smelling and touching) were ignored.
Female Urine Sniffing Test
The female Urine Sniffing Test (FUST) is a non-operant test for measuring 
reward-seeking behaviour in rodents based on interest in sniffing pheromones 
odours from opposite sex, and was conducted as described previously 
(Malkesman et al., 2012). Briefly, the test had three phases: (1) a single 
exposure (3 min) to the cotton tip dipped in sterile water, during which the time 
spent sniffing the applicator was measured; 2 an interval of 45 min during which 
no applicator was presented to the animal; and (3) a single exposure (3 min) to 
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a cotton tip infused with fresh urine collected from females of the same strain in 
oestrus or water, during which the time spent sniffing was measured.
The animals receiving GAL(1-15) 3nmol or vehicle were injected 15 min before 
to the exposure to the urine or water (phase 3).
PET Studies
Ten or eleven days after surgery, the animals (n=8; 335 ± 38 g) were fasted 
overnight and anaesthetized with isoflurane inhalation (5 % for induction and 
2 % for maintenance in 100% oxygen gas). Animals were administered icv with 
aCSF and after 3-4 days with Gal(1-15) (3 nmol). Immediately thereafter the 
treatment, the 18F-FDG (43.6 ± 5.5 MBq in 0.3 ml of 0.9% NaCl) was injected 
through the tail vein. After an awake uptake period of 25 minutes to ensure the 
incorporation of 18F-FDG during drug-induce behavioural effects (Prieto et al., 
2011), animals were anesthetized and placed prone on the PET scanner bed to 
perform a static acquisition of 30 min at three different time-points (30, 60 and 
90 min) after tracer administration. The images were subsequently 
reconstructed using an iterative 3-D row action maximum likelihood algorithm 
(3-D RAMLA), with 2 iterations and a relaxation parameter of 0.024. Corrections 
for dead time, decay and random coincidences were applied. Images were 
reconstructed on a 128 × 128 × 120 matrix, where the voxel size equals 1 × 1 × 
1 mm. 
Blood glucose concentration (128 ± 24 mg/dl) was determine before 
tracer injection, using a glucose level meter with test strips (Accu Chek Aviva 
Nano, Roche, Mannhelm, Germany). 
Image preprocessing
The image preprocessing was performed using PMOD (PMOD 
Technologies, Zürich, Switzerland; https://www.pmod.com/web/), SPM8 
(Wellcome Department of Imaging Neuroscience, London, UK; 
http://www.fil.ion.ucl.ac.uk/spm/software/spm8/), SAMIT (Small Animal 
Molecular Imaging Toolbox created by University Medical Center Groningen for 
SPM, Groningen, Netherlands; http://mic-umcg.github.io/samit/) and a custom-
made software develop using MATLAB R2015b (Mathworks; 
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https://es.mathworks.com/products/new_products/release2015b.html) to 
normalize the 18F-FDG uptake values to a whole brain average value. 
The PET images were initially manually matched using PMOD Fusion 
toolbox to a T2-MRI rat template of SAMIT (Technologies, 2016), which is in 
Paxinos and Watson anatomical space (Schwarz et al., 2006; (UMCG). 2015). 
This coregister included several rotations and translations in each of the three 
dimensions (x, y and z) to match the location, and orientation of the T2 template. 
Afterwards, the coregistered images were spatially normalized to a FDG rat 
template provided by SAMIT (Vallez Garcia et al., 2015) in SPM8, skull stripped 
(removing any extracerebral activity) and smoothed with a Gaussian kernel of 
1.2*1.2*1.2 full width at half-maximum (FWHM) to remove any non-uniformities. 
Finally, custom-made software was used to normalize the values of the 18F-
FDG uptake in each image to the average brain uptake value.
Genes expression in VTA and NAc
Rats from NSF and FUST experiment (Fig. 1B) were killed by decapitation 1h 
after a single i.c.v. administration of GAL(1-15) 3 nmol or vehicle and the brains 
were rapidly removed and frozen until its use. The nuclei dissections were 
conducted as described (Garcia-Perez et al., 2016) with modifications. Brains 
were sliced on the brain matrix (1mm) and kept -20ºC until each region of 
interest comes into the cutting plane. For VTA analysis, one 1 mm coronal brain 
section was obtained from bregma -6.04 mm (Paxinos, 1986). For NAc study, 
two consecutive 1mm coronal slices were made corresponding to approximate 
bregma +1.2 mm (Paxinos, 1986). Tissues of interest were dissected using a 
punching device with 2 mm internal diameter. Bilateral punches of the NAc and 
VTA (Fig. 4 and 6) were collected into Eppendorf tubes.
RNA isolation and quantitative real-time polymerase chain reaction 
analysis
Total RNA was isolated from the punches of NAc and VTA using RNeasy Lipid 
Tissue Kit (Qiagen, Hilden, Germany). cDNA was obtained using a Reverse 
Transcriptase Core Kit (Eurogentec, Seraing, Belgium). These steps were 
performed according to the manufacturer’s instructions.
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All PCR were conducted in triplicate using FastStart essential DNA green 
master (Roche Diagnostics GmbH, Mannchem, Germany) in LigtCycler 96 
system (Roche Diagnostics GmbH, Mannchem, Germany).
The data were analysed using the comparative Ct method and normalized to 
measures of glyceraldehyde- 3-phosphate dehydrogenase (GAPDH) mRNA.
Tyrosine Hydroxylase immunohistochemistry
Rats from NSF and FUST experiment (Fig. 1B) were perfused trascardially 90 
min after a single i.c.v. administration of GAL(1-15) 3 nmol or vehicle. The 
brains were then dissected and serial, coronal free-floating sections (30 μm 
thick) were collected. The sections were incubated with a primary antibody 
rabbit anti-TH (Sigma, 1/2000) overnight at 4ºC. An hour incubation with 
biotinylated, specific secondary antibodies (1:200; Vector Labs Inc) was 
performed at room temperature. The chromogen used was 0.03% 3-30-
diaminobenzidine tetrahydrochloride (Sigma).
Analysis of TH Immunoreactivity was performed under light microscopy (Nikon 
Optiphot-2) in the neuro-anatomical area of interest. Three sections per animal 
were examined and captured by a video camera (Olimpus UC30) linked to a PC 
computer, and TH immunoreactivity was quantified by optical density using the 
computer software ImageJ (National Institutes of Health).
Double Immunofluorescence
The procedures have been previously used (Millon et al., 2015). Primary 
antibody rabbit anti-GAL2 receptor (Alomone Lab, 1/250) was incubated for 12 
hours at 4ºC and detected with the red secondary antibody mouse anti-rabbit 
DyLight 549 (Jackson inmunoResearch Laboratories, 1/100). Goat anti-GAL1 
receptor (Santa Cruz Biotechnology INC, EEUU, 1:250) was incubated 12 hours 
at 4ºC and detected with the secondary antibody rabbit biotynilated anti-goat 
(Vector Labs Inc.) and Alexa Fluor 488-conjugated Streptavidin (Jackson 
Laboratories InmunoResearch, 1:1000). Sections were mounted on slides with 
fluorescent mounting medium (Dako) and visualized using a Leica SP8 confocal 
microscope. The double immunolabeling was performed in the tissue of rats 
without treatment (Figure S1).
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Treatment 2h 8h 24h 
Control 3.13±0.77 7.46±1.49 9.97±1.64
GAL(1-15) 3nmol 8.55±2.58 13.47±3.12 16.58±2.90
Table S2. Water intake (g/Kg) in Sucrose Preference Test.
Table S2. Effect of administration of Galanin (1-15) [GAL(1-15)] in the water 
intake in Sucrose Preference Test with 1% sucrose concentration in rats. 
GAL(1-15) (3nmol/rats; n= 8-9 animals per group) were administrated 
intracerebroventricular 2, 8 and 24 hours before the measures. Cerebrospinal 
fluid-injected rats were used as the Control group (n= 7 animals). Data 
represent the mean ± standard error of the mean of water intake (g/Kg). No 
significant differences were found by repeated measures two-way ANOVA.
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Figure S1. Galanin Receptor 1 (GALR1) and Galanin Receptor 2 (GALR2) 
colocalizes in neurons of rat striatum and Ventral Tegmental Area. Double-
immunolabeled for GALR1 (green, arrows) and GALR2 (red, arrowhead) in (A) 
Ventral Tegmental Area (VTA), (B) Accumbens nucleus Core (NAcC), (C) 
Accumbens nucleus Shell (NAcSh) and (D) Caudate Putamen (Cpu). The 
colocalization of GALR1 and GALR2 is shown in the merge (orange-yellow, 
rhombus. Escale bar, 25-50 μm.
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